{"schema_version":"1.0","type":"article","title":"A New Drug Launched. Seven Months Later, the Company Sought Liquidation","url":"https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley-en.md","lang":"en","date":"2026-09-02","publish_at":"2026-09-02T08:00:00+08:00","updated_at":"2026-09-02","category":"商業分析系列","topic":"商業分析系列","tags":["biotech commercialization","Iterum Therapeutics","ORLYNVAH","Karyopharm","XPOVIO","Theravance Biopharma","drug launch","biotech finance","cash runway","biopharma"],"summary":"FDA approval does not erase business risk. Iterum, Karyopharm and Theravance show how revenue, cost, pipeline and capital clocks can begin running at the same time after a drug reaches the market.","key_points":[],"facts":[],"sections":["01 | Iterum: $0.4 million in revenue collided with $6.5 million in expense","02 | Karyopharm: a first-in-class target could not rescue the balance sheet","03 | Theravance: not unable to continue, but unwilling to wager its cash on the next bet","04 | Real commercialization capability is not simply selling a drug","05 | Before judging a commercial biotech, look at four clocks","06 | The real warning for biotech companies in Taiwan and China","Conclusion | The FDA grants a ticket, not a life-support machine","Primary Sources"],"references":[{"title":"[Iterum","source":"Third-quarter 2025 financial results]","date":"","url":"https://ir.iterumtx.com/press-releases/detail/159/iterum-therapeutics-reports-third-quarter-2025-financial"},{"title":"[Iterum","source":"Liquidation application and provisional liquidation]","date":"","url":"https://www.sec.gov/Archives/edgar/data/1659323/000119312526127785/itrm-20260327.htm"},{"title":"[Iterum","source":"Announcement following the court liquidation order]","date":"","url":"https://content.bsx.com/CompanyDocuments/1099939718/Iterum%20-%20BSX%20Announcement%20-%201%20June%202026.pdf"},{"title":"[Karyopharm","source":"Second-quarter 2026 financial results]","date":"","url":"https://investors.karyopharm.com/2026-08-13-Karyopharm-Reports-Second-Quarter-2026-Financial-Results-and-Highlights-Continued-Progress-Toward-Myelofibrosis-sNDA-Submission"},{"title":"[Karyopharm","source":"Phase 3 SENTRY results]","date":"","url":"https://investors.karyopharm.com/2026-06-02-Karyopharm-to-Present-Results-from-Phase-3-SENTRY-Trial-of-Selinexor-Plus-Ruxolitinib-in-Myelofibrosis-in-Late-Breaking-Oral-Presentation-at-ASCO-2026-with-Simultaneous-Publication-in-the-Journal-of-Clinical-Oncology"},{"title":"[Karyopharm","source":"Myelofibrosis filing pathway]","date":"","url":"https://investors.karyopharm.com/2026-07-30-Karyopharm-Plans-to-Submit-sNDA-for-Selinexor-Plus-Ruxolitinib-in-Myelofibrosis-Under-Accelerated-Approval-Pathway"},{"title":"[Theravance","source":"Phase 3 CYPRESS and restructuring]","date":"","url":"https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-reports-phase-3-cypress-study-did-not-meet"},{"title":"[Theravance","source":"Second-quarter 2026 financial results and pending acquisition]","date":"","url":"https://investor.theravance.com/news-releases/news-release-details/theravance-biopharma-inc-reports-second-quarter-2026-financial"},{"title":"This article is for pharmaceutical-industry and investment education. It does not constitute medical or investment advice. Company status and regulatory progress are current only through August 26, 2026. Karyopharm has not entered bankruptcy, and the Theravance–Zymeworks transaction remained pending as of the verification date.","source":"","date":"","url":""}],"images":[{"alt":"Figure 1: A drug launch starts four clocks at once—revenue, cost, pipeline and capital","url":"https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley-en/cover.png"},{"alt":"Figure 2: Iterum's seven-month commercialization countdown—$0.4 million in revenue versus $6.5 million in expense","url":"https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley-en/figure-02.png"},{"alt":"Figure 3: Karyopharm's stress test—product revenue, cash, debt and new indications counting down together","url":"https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley-en/figure-03.png"},{"alt":"Figure 4: Three outcomes—Iterum liquidation, Karyopharm stress test and Theravance value exit","url":"https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-02）。A New Drug Launched. Seven Months Later, the Company Sought Liquidation。https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-09-02-post-approval-biotech-commercialization-death-valley.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}